Objectives: To compare renal function after radical nephrectomy for renal cell carcinoma (RCC) and for upper tract urothelial carcinoma (UTUC). Method: Data from 1,236 patients with RCC or UTUC treated surgically from 2000 to 2013 were enrolled. The estimated glomerular filtration rate (eGFR) was calculated preoperatively and postoperatively at 12, 24, 36, 48, and 60 months. A multivariate logistic regression was used to determine independent factors for a decrease in eGFR to < 60 mL/min/1.73 m2 and end-stage renal disease. Result: After propensity score matching, a total of 554 patients were included. During follow-up for 5 years, there was statistically significant difference in eGFR between 2 groups. And there was a statistically significant difference in the number of patients developing impaired renal function between the 2 groups (UTUC 73.3 vs. RCC 66.1%, p = 0.039). Multivariate analysis showed that old age (OR 3.957, p < 0.001), UTUC (OR 1.838, p = 0.006), BMI (OR 2.463, p = 0.001) and a baseline eGFR (OR 0.976, p = 0.001) were independent risk factors for postoperative impaired renal function. Conclusion: Patients with UTUC had worse baseline eGFR, old age, comorbidities than RCC patients. Even after adjusting by PS matching, UTUC patients had lower postoperative eGFR and higher rates of CKD development than RCC patients.

Keywords:
Urothelial carcinoma, Renal cell carcinoma, Renal function, Radical nephrectomy
1.
Chow WH, Dong LM, Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245–257.
2.
Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA: Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set: Elsevier Health Sciences), 2011.
3.
Dinkel E, Britscho J, Dittrich M, Schulte-Wissermann H, Ertel M: Renal growth in patients nephrectomized for Wilms tumour as compared to renal agenesis. Eur J Pediatr 1988; 147: 54–58.
4.
Schmitz A, Christensen C, Christensen T, Sølling K: No microalbuminuria or other adverse effects of long-standing hyperfiltration in humans with one kidney. Am J Kidney Dis 1989; 13: 131–136.
5.
Kasiske BL, Ma JZ, Louis TA, Swan SK: Long-term effects of reduced renal mass in humans. Kidney Int 1995; 48: 814–819.
6.
Narkun-Burgess DM, Nolan CR, Norman JE, Page WF, Miller PL, Meyer TW: Forty-five year follow-up after uninephrectomy. Kidney Int 1993; 43: 1110–1115.
7.
Lee SH, Kim DS, Cho S, Kim SJ, Kang SH, Park J, Park SY, Chang SG, Jeon SH: Comparison of postoperative estimated glomerular filtration rate between kidney donors and radical nephrectomy patients, and risk factors for postoperative chronic kidney disease. Int J Urol 2015; 22: 674–678.
8.
Timsit MO, Nguyen KN, Rouach Y, Elie C, Loupy A, Fournier C, Legendre C, Mejean A: Kidney function following nephrectomy: similitude and discrepancies between kidney cancer and living donation. Urol Oncol2012; 30: 482–486.
9.
Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115–124.
10.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Int Med 1999; 130: 461–470.
11.
Singla N, Hutchinson R, Menegaz C, Haddad AQ, Jiang L, Sagalowsky AI, Cadeddu JA, Lotan Y, Margulis V: Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma. Urology 2016; 96: 44–53.
12.
Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ: Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010; 116: 2967–2973.
13.
Kaag MG, O’Malley RL, O’Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC: Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 2010; 58: 581–587.
14.
Song W, Sung HH, Han DH, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Jeon HG: The effect of contralateral kidney volume on renal function after radical nephroureterectomy: implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer. Urol Oncol 2017; 35: 114.e1–e7.
15.
Ouzzane A, Roupret M, Leon P, Yates DR, Colin P: [Epidemiology and risk factors of upper urinary tract tumors: literature review for the yearly scientific report of the French National Association of Urology]. Prog Urol 2014; 24: 966–976.
16.
Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT, Russo P: Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735–740.
17.
Malcolm JB, Bagrodia A, Derweesh IH, Mehrazin R, Diblasio CJ, Wake RW, Wan JY, Patterson AL: Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. BJU Int 2009; 104: 476–481.
18.
Kong HJ, Park JS, Kim DY, Shin HS, Jung HJ: Renal function following curative surgery for renal cell carcinoma: who is at risk for renal insufficiency? Korean J Urol 2013; 54: 830–833.
19.
Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, Shariat SF, Maschino A, Vertosick E, Raman JD, Dalbagni G: Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int 2014; 114: 674–679.
20.
Lane BR, Babineau DC, Poggio ED, Weight CJ, Larson BT, Gill IS, Novick AC: Factors predicting renal functional outcome after partial nephrectomy. J Urol 2008; 180: 2363–2368.
21.
Kim SH, Lee SE, Hong SK, Jeong CW, Park YH, Kim YJ, Kang SH, Hong SH, Choi WS, Byun SS: Incidence and risk factors of chronic kidney disease in korean patients with t1a renal cell carcinoma before and after radical or partial nephrectomy. Jpn J Clin Oncol 2013; 43: 1243–1248.
22.
Breau RH, Clark E, Bruner B, Cervini P, Atwell T, Knoll G, Leibovich BC: A simple method to estimate renal volume from computed tomography. Can Urol Assoc J 2013; 7: 189–192.
23.
Gorbatiy V, Iremashvili V, Castro A, Mure A, Ortiz N, Castle SM, Leveillee RJ: Renal volumetric analysis: a new paradigm in renal mass treatment assessment. J Endourol 2013; 27: 361–365.
24.
Richards KA, Negron E, Cohn JA, Steinberg Z, Eggener SE, Shalhav AL: The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy. J Endourol 2014; 28: 1338–1344.
25.
Nozaki T, Ishida H, Tokumoto T, Shirakawa H, Shimizu T, Omoto K, Uchida K, Nitta K, Tanabe K: Risk factors for deterioration of renal function after donor nephrectomy. Transplant Proc 2010; 42: 1476–1478.
26.
Prassopoulos P, Cavouras D, Gourtsoyiannis N: Pre- and post-nephrectomy kidney enlargement in patients with contralateral renal cancer. Eur Urol 1993; 24: 58–61.
27.
Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Bohle A, Burger M, Comperat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, et al: Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 2016; 70: 1052–1068.
28.
Nativ O, Bahouth Z, Sabo E, Halachmi S, Moskovitz B, Hellou EG, Abassi Z, Nativ O: Method used for tumor bed closure (suture vs. sealant), ischemia time and duration of surgery are independent predictors of post-nephron sparing surgery acute kidney injury. Urol Int 2018; 101: 184–189.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.